01 / Product stage

Reported evidence

COMP360 is investigational synthetic psilocybin for TRD. Two pivotal Phase 3 trials, COMP005 and COMP006, met their primary endpoints. As of the September 9 announcement, rolling NDA submission and review were underway. Completing the final submission in Q4 2026 and launching in the first half of 2027 are company expectations, conditional on regulatory decisions. A submission is not an approval. [1, 4]

02 / Treatment evidence

Reported evidence

At week 6, COMP005 reported an adjusted MADRS difference of −3.6 points versus placebo (95% CI −5.7 to −1.5). COMP006 reported −3.8 points for two 25 mg doses versus two 1 mg doses (95% CI −5.8 to −1.8). Both p-values were below .001. Lower MADRS scores mean fewer depressive symptoms; these are differences in change between groups, not the entire improvement of each patient. [1]

What the September update adds

Reported evidence

The company reported an average 13-point reduction from baseline at week 52 among original 25 mg participants who continued into open-label Part C and received another dose. This selected group and repeated dosing matter: the result does not establish that one dose benefits every patient for a year. Open-label follow-up provides useful durability information, with weaker causal control than a blinded comparison. [4]

03 / Commercial delivery

My interpretation

The treatment model involves a multi-hour session with monitoring and support. My inference is that room time, staffing, preparation, follow-up and reimbursement will affect clinic economics. Published efficacy does not establish a cost per successful treatment. I am not assigning a staffing ratio or claiming that clinics will be profitable.

04 / Cash position

Reported evidence

Cash and equivalents were $433.3 million at June 30, 2026; debt was $50.7 million. Management forecast funding into 2028. That is guidance, not a guaranteed date. Q2 net loss included a large noncash warrant valuation adjustment, so net loss should not be treated as cash burned. [5]

05 / Financing and the next checkpoint

Reported evidence

In February, outstanding warrant exercises generated about $200 million in gross proceeds. This is financing through existing warrants, not product revenue. Issuing shares or share equivalents can dilute existing holders. Next I will watch completion of the NDA, regulatory requirements for delivery, and actual provider and payer economics. [6]

Sources

Plain-text references. Financial balances are dated June 30, 2026; source review completed October 6, 2026.

  1. Compass Pathways. Second Phase 3 COMP360 primary-endpoint announcement. February 17, 2026.
  2. Compass Pathways. 52-week open-label COMP005 Part C topline results. September 9, 2026.
  3. Compass Pathways. Second Quarter and First Half 2026 Financial Results and Business Highlights. August 5, 2026.
  4. Compass Pathways. Exercise of $200 Million in Outstanding Warrants. February 26, 2026.